| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/26/2010 | CN101712721A T cell receptor fusions and conjugates and methods of use thereof |
| 05/26/2010 | CN101712720A Human antibodies that bind human TNF alpha |
| 05/26/2010 | CN101712719A Preparation method and application of humanized neutralized anti-influenza NS1 genetic engineering antibody |
| 05/26/2010 | CN101711877A Chitosan vehicle and method for making same |
| 05/26/2010 | CN101711868A Gene detection assay for improving the likelihood of an effective response to a ErbB antibody cancer therapy |
| 05/26/2010 | CN101711867A Pinctada martensii dunker antibody vital injection experimental method |
| 05/26/2010 | CN101711866A Method for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| 05/26/2010 | CN101711865A vaccine compositions containing amyloid beta1-6 antigen arrays |
| 05/26/2010 | CN101711864A gm-negative ehv-mutants without heterologous elements |
| 05/26/2010 | CN101711863A Vaccine eye drops used for treating and preventing glaucoma and preparation method |
| 05/26/2010 | CN101711861A bacterial virulence factors and uses thereof |
| 05/26/2010 | CN101711859A Application of Hfq protein of staphylococcus aureus in preventing and treating staphylococcus aureus infection |
| 05/26/2010 | CN101147807B Substances for preventing and treating autoimmune diseases |
| 05/26/2010 | CN101057976B Substances for preventing and treating autoimmune diseases |
| 05/25/2010 | US7723570 Transgenic soybean or soy protein product and a mutant cholera toxin adjuvant; the soybean is transformed with an exogenous nucleotide sequence that expresses Staphylococcus enterotoxin B; the mutant cholera toxin adjuvant is coexpressed with the SEB or is added separately |
| 05/25/2010 | US7723504 Nontypeable Haemophilus influenzae virulence factors |
| 05/25/2010 | US7723500 Containing unmethylated CpG dinucleotides; redirection of a Th2 response to a Th1 response; atopic diseases, dermatitis; booster vaccines |
| 05/25/2010 | US7723490 Process for correction of a disulfide misfold in Fc molecules |
| 05/25/2010 | US7723485 Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| 05/25/2010 | US7723482 Preventing CD28 binding to B7 by monovalent fragments antibody called CD28.3 of which exhibit sufficient affinity for the antigen so that they can be used, in vitro or in vivo, to block the CD28 receptor without activation of this receptor; autoimmune diseases; transplant rejection |
| 05/25/2010 | US7723479 BSL3 polypeptides |
| 05/25/2010 | US7723357 Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposus |
| 05/25/2010 | US7723295 Peptides and compounds that bind to a receptor |
| 05/25/2010 | US7723288 Methods and compositions for the treatment of neurological disease |
| 05/25/2010 | US7723111 Anticancer agents; autoimmune disease |
| 05/25/2010 | US7723107 Pharmaceutical composition for inducing an immune response in a human or animal |
| 05/25/2010 | US7723096 Agonist peptides of carcinoembryonic antigen (CEA) and nucleic acid sequences encoding the agonist peptides |
| 05/25/2010 | US7723080 Murine α (1,3) fucosyltransferase Fuc-TVII, DNA encoding the same, method for preparing the same, antibodies recognizing the same, immunoassays for detecting the same, plasmids containing such DNA, and cells containing such a plasmid |
| 05/25/2010 | US7723073 Nucleic acid sequences containing a coding sequence for a light chain of an anti-VLA-1 antibody or antigen binding fragment, and a coding sequence for a heavy chain of an anti-VLA-1 antibody or fragment; the light chain and the heavy chain form an antibody or fragment that binds VLA-1 |
| 05/25/2010 | US7723055 Using aberration in wingless (WNT) gene expression as evaluating tool in diagnosis/prognosis of cell proliferative disorders |
| 05/25/2010 | US7723044 Methods and apparatus for detection of viral infection |
| 05/25/2010 | US7723022 Oligonucleotide containing activated lymphocytes; antibody therap y; skin disorders; antiallergens; respiratory system disorders |
| 05/25/2010 | US7722890 Immunogens based on beta -D-mannopyranose; cell wall oligosaccharides similar to beta-mannans |
| 05/25/2010 | US7722889 Plasmodium liver stage antigens |
| 05/25/2010 | US7722888 Streptococcus pneumoniae proteins and nucleic |
| 05/25/2010 | US7722887 detoxified and immunologically active heat-labile enterotoxin protein of Escherichia coli, wherein the serine residue at position 63 is substituted with tyrosine or amino acid residues at positions 110 and 112 are deleted; for development of a mucosal vaccine as well as a novel diarrheal vaccine |
| 05/25/2010 | US7722886 Therapeutic agent comprising cytokine inhibitory activity for use in treatment of respiratory system disorders; viricides; antisense agents; enzyme inhibitors; immunotherapy; RNA interference; recombinant cytokine receptors |
| 05/25/2010 | US7722885 Dengue virus mutant strain MBU 01-2002 |
| 05/25/2010 | US7722884 Vaccines and methods to treat canine influenza |
| 05/25/2010 | US7722883 Genetic vaccine against PWD circovirus |
| 05/25/2010 | US7722882 Live attenuated vaccine against porcine pleuropneumonia |
| 05/25/2010 | US7722881 Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof |
| 05/25/2010 | US7722880 polynucleotide encodes a protein for inducing an immune response; use as vaccines; drug targeting to specific protein; bactericides; veterinary medicine |
| 05/25/2010 | US7722879 amino acid sequence proteins or immunogenic fragments, encoded sequence from isolated nucleic acid; for treating infection caused from Babesiidae; diagnostic test for the detection of nucleic acids, antibodies or antigens of the organism; safe, stable, easily scaleable production; veterinary medicine |
| 05/25/2010 | US7722878 compositions provide immune response up to and including protective immunity against porcine reproductive and respiratory syndrome (PRRS) as well as reduce the severity of PRRS virus (PRRSV) and/or incidence of PRRSV |
| 05/25/2010 | US7722877 Coccidiosis vaccines |
| 05/25/2010 | US7722875 Antibodies that bind canine pancreatic lipase |
| 05/25/2010 | US7722874 Methods for reducing T cell responsiveness to an autoantigen with anti-gp39 antibodies and antigen presenting cells |
| 05/25/2010 | US7722873 Specific for human CD4 antigens; monoclonal antibodies; immunoglobulins; inflammatory disease, reperfusion injury, infectious disease, blood disorder, and transplant rejection |
| 05/25/2010 | US7722872 Treatment of cancer with antibodies to costimulating polypeptide of T cells |
| 05/25/2010 | US7722871 Immunoglobulins devoid of light chains |
| 05/25/2010 | US7722870 Method of treating fibroproliferative disorders |
| 05/25/2010 | US7722869 purified scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer, and scFv peptide comprises a substitution of an amino acid in the VH domain at the position corresponding to C28 |
| 05/25/2010 | US7722868 Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof |
| 05/25/2010 | US7722867 Nucleotide sequences coding chimeric immunoglobulin specific for epidermal growth factor receptor; treatment and prevention of cell proliferative disorders |
| 05/25/2010 | US7722866 using a monoclonal antibody or an antigen-binding portion which binds to an epitope of EphB4 polypeptide and inhibiting the growth of cancer as a result of such binding by causing cell death |
| 05/25/2010 | US7722862 Regulatory T cells suppress autoimmunity |
| 05/25/2010 | US7722861 Attenuated Mycobacterium tuberculosis vaccines |
| 05/25/2010 | US7722860 administering to animal or bird a live protozoan parasite that is genetically engineered to disrupt a stage-specific gene function that is required by the protozoan parasite to establish a secondary infection in the vertebrate host; protozoan parasites belong to the phyla Apicomplexa and Kinetoplastida |
| 05/25/2010 | US7722857 one or more kinds of immunostimulating substances carried separately by two or more kinds of microparticle immunostimulating substance carriers and comprising a combination of inorganic substance such as microparticle calcium phosphate and precipitates of soluble protein and mucopolysaccharide; antitumor |
| 05/25/2010 | CA2375727C Cytofectin dimers and methods of use thereof |
| 05/25/2010 | CA2354928C Non-mucin type synthetic compounds or it's carrier conjugated compounds |
| 05/25/2010 | CA2321964C Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus |
| 05/25/2010 | CA2218857C Clostridial toxin derivatives able to modify peripheral sensory afferent functions |
| 05/25/2010 | CA2199715C Novel implant and novel vector for the treatment of acquired diseases |
| 05/25/2010 | CA2170142C Composition and method for stimulation of reproductive performance |
| 05/20/2010 | WO2010057175A1 Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same |
| 05/20/2010 | WO2010057109A1 Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| 05/20/2010 | WO2010057107A1 Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| 05/20/2010 | WO2010057047A1 Cd37 immunotherapeutic combination therapies and uses thereof |
| 05/20/2010 | WO2010056991A1 Vaccine formulations and uses thereof |
| 05/20/2010 | WO2010056981A2 Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
| 05/20/2010 | WO2010056948A2 Humanized anti-il-6 antibodies |
| 05/20/2010 | WO2010056910A2 Methods of treating cardiovascular disorders |
| 05/20/2010 | WO2010056804A1 Antibody formulation |
| 05/20/2010 | WO2010056796A1 Human m2e peptide immunogens |
| 05/20/2010 | WO2010056709A2 Eimeria vaccine for turkeys |
| 05/20/2010 | WO2010056399A1 Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| 05/20/2010 | WO2010056148A1 Mucosal vaccine for immunotherapy of diseases caused by human papillomaviruses |
| 05/20/2010 | WO2010056143A1 The use of adjuvant to facilitate the induction of immune tolerance |
| 05/20/2010 | WO2010055950A1 Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound |
| 05/20/2010 | WO2010055900A1 Method for producing dendritic cells |
| 05/20/2010 | WO2010055500A1 A vaccinia virus protein a46 peptide and use thereof |
| 05/20/2010 | WO2010055413A1 Gene vector for inducing transgene-specific immune tolerance |
| 05/20/2010 | WO2010054855A1 A medicament |
| 05/20/2010 | WO2010054654A1 Modified cationic liposome adjuvans |
| 05/20/2010 | WO2010054649A2 Method for the oral/mucosal vaccination by means of recombinant yeasts |
| 05/20/2010 | WO2010054482A1 Immunogenic human papillomavirus compositions |
| 05/20/2010 | WO2010054437A1 Vaccine strains of brachyspira hyodysenteriae |
| 05/20/2010 | WO2010054424A1 Agents and treatment for snoring and respiratory effort related arousals in sleep |
| 05/20/2010 | WO2010037395A3 Mhc multimers in cancer vaccines and immune monitoring |
| 05/20/2010 | WO2010037027A3 Immunization of avians by mucosal administration of non-replicating vectored vaccines |
| 05/20/2010 | WO2010036945A3 Nanoemulsion therapeutic compositions and methods of using the same |
| 05/20/2010 | WO2010025321A3 Method for treating multiple sclerosis patients with anti-il2r antibodies |
| 05/20/2010 | WO2010022017A3 Method and composition for enhancing hematopoietic stem cell mobilization |
| 05/20/2010 | WO2010012004A3 Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
| 05/20/2010 | WO2010011315A3 Proteins for use in diagnosing and treating infection and disease |
| 05/20/2010 | WO2010009987A3 Diagnostic antibody assay |
| 05/20/2010 | WO2010009856A3 Goodpasture antigen binding protein and its detection |
| 05/20/2010 | WO2010003002A9 Modulation of follicular helper t cells |